Findings underscore how earlier detection, diagnosis can alter progress of disease. Read more at straitstimes.com.
AMSTERDAM - Pharmaceutical company Eli Lilly’s experimental drug donanemab slowed the progression of Alzheimer’s by 60 per cent for patients in the earliest stages of the brain-wasting disease, according to trial data presented at a medical meeting on Monday.for the trial’s overall treatment group.
The study showed that brain swelling, a known side effect of drugs like donanemab, occurred in more than 40 per cent of patients with a genetic predisposition to develop Alzheimer’s. Donanemab, like Eisai and Biogen’s recently approved Leqembi, is an intravenous antibody designed to remove deposits of a protein called beta amyloid from the brains of Alzheimer’s patients.
She said the findings support the idea that donanemab can be stopped once amyloid is cleared from the brain. The full study results were presented at the Alzheimer’s Association International Conference in Amsterdam and published in American medical journal Jama.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Jacky still Ooh La La at 60+Four days after he turned 62, Hong Kong megastar Jacky Cheung proved that age is just a number on the opening night of his 60+ Concert Tour in Singapore. He told the capacity-filled 8,000 crowd at the Singapore Indoor Stadium last night: 'In the past, I didn't...
続きを読む »
Alzheimer's diagnosis revamp embraces rating scale similar to cancerExperts are devising a seven-point rating scale based on cognitive and biological changes in the patient. Read more at straitstimes.com.
続きを読む »
New US-approved drug for early-stage Alzheimer’s disease not yet available hereHealth Sciences Authority says doctors here may apply for use on a named patient basis. Read more at straitstimes.com.
続きを読む »
Alzheimer's diagnosis revamp embraces rating scale similar to cancerAlzheimer's disease experts are revamping the way doctors diagnose patients with the progressive brain disorder - the most common type of dementia - adopting a seven-point rating scale based on cognitive and biological changes in the patient. The new guidelines, unveiled by experts on Sunday in a report is
続きを読む »
Commentary: Young-onset Alzheimer’s can be diagnosed from as early as 30 – here’s what to look out forWhat are the first signs of young-onset Alzheimer’s disease? It isn't memory loss and mistaking the symptoms can put people off seeking medical help, says a University of Reading neuroscientist.
続きを読む »
Alzheimer's diagnosis revamp embraces rating scale similar to cancerAlzheimer's disease experts are revamping the way doctors diagnose patients with the progressive brain disorder - the most common type of dementia - adopting a seven-point rating scale based on cognitive and biological changes in the patient. The new guidelines, unveiled by experts on Sunday in a report is
続きを読む »